Skip to content

Does pre-pregnancy levothyroxine treatment will improve the in vitro fertilization outcomes? A randomized placebo controlled clinical trial

Does pre-pregnancy levothyroxine treatment will improve the in vitro fertilization outcomes? A randomized placebo controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15007426
Enrollment
Unknown
Registered
2015-11-20
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical hypothyroidism, infertility

Interventions

Levothyroxine arm:Levothyroxine treatment

Sponsors

Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Women have a duration of infertility >=1 year; 2. Women ages >=20 and <40 years old; 3. Women who are undergoing their first cycle of IVF or ICSI; 4. Women with TSH level 2.5~4mIU/L and normal free thyroxine.

Exclusion criteria

Exclusion criteria: 1. Women who are taking thyroid medicine or medicines interfering thyroid metabolism for last 2 months; 2. Women who have previously been diagnosed with a uterine abnormality such as a malformed uterus (uterus unicornis, septate uterus, duplex uterus or uterus bicomis), adenomyosis, submucous myoma or intrauterine adhesion; 3. Women or their partners with an abnormal chromosome karyotype; 4. Women with medical conditions that contraindicate assisted reproductive technology and/or pregnancy, such as poorly controlled diabetes mellitus; undiagnosed liver disease or dysfunction (based on serum liver enzyme test results); undiagnosed renal disease or abnormal serum renal function; severe anemia; history of deep venous thrombosis, pulmonary embolus or cerebrovascular accident; uncontrolled hypertension or symptomatic heart disease; history of (or suspected) cervical carcinoma, endometrial carcinoma or breast carcinoma; and undiagnosed vaginal bleeding.

Design outcomes

Primary

MeasureTime frame
Live birth rate;children IQ at 60 months old;

Countries

China

Contacts

Public ContactZi-Jiang Chen
chenzijiang@vip.163.com+86 021-20284579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026